Quick Takeaways
- CITADEL ADVISORS LLC filed SCHEDULE 13G/A for BridgeBio Oncology Therapeutics, Inc. Class A ordinary share, par value $0.0001 per share (the "Shares") (BBOT).
- Disclosed ownership: 3.2%.
- Date of event: 30 Sep 2025.
Quoteable Key Fact
"CITADEL ADVISORS LLC disclosed 3.2% ownership in BridgeBio Oncology Therapeutics, Inc. Class A ordinary share, par value $0.0001 per share (the "Shares") (BBOT) on 30 Sep 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Citadel Advisors LLC | 3.2% | 2,528,762 | 0 | 2,528,762 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Advisors Holdings LP | 3.2% | 2,528,762 | 0 | 2,528,762 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel GP LLC | 3.2% | 2,528,762 | 0 | 2,528,762 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Securities LLC | 0% | 9,380 | 0 | 9,380 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Securities Group LP | 0% | 9,380 | 0 | 9,380 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Securities GP LLC | 0% | 9,380 | 0 | 9,380 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Kenneth Griffin | 3.2% | 2,538,142 | 0 | 2,538,142 | /s/ Seth Levy | Seth Levy, attorney-in-fact* |